go top

progression-free survival

  • 无进展生存期:在癌症治疗中,患者在没有疾病进展的情况下存活的时间。

网络释义专业释义英英释义

  无进展生存期

这项临床试验的主要终点是无进展生存期(progression-free survival):卡博替尼的无进展生存期是中值8.2个月,而对舒尼替尼而言,这一数字是5.6个月。

基于270个网页-相关网页

  存活期

据新英格兰医学杂志报道,这两只药物能延长患者一倍的存活期progression-free survival),即从5.5个月到11个月。

基于110个网页-相关网页

  无进展生存时间

...。3组的治疗均持续至患者出现疾病进展或出现无法耐受的不良反应或死亡。研究的主要终点为中位无进展生存时间(progression-free survival,PFS)和12个月PFS率,次要终点为总体缓解率、安全性/不良反应。结果:随访中A、C组各失访1例。

基于74个网页-相关网页

  存活率

髓母细胞瘤的5年无恶化 存活率 (progression-free survival)是66.46%。

基于58个网页-相关网页

短语

overall and progression-free survival 与无恶化存活期

progression-free survival rate 无病存活率

progression free survival time 进展生存期 ; 无进展生存期

progression-free survival PFS 时间

median progression free survival 和中位无进展生存期

PFS- Progression Free Survival 无进展生存期

progression-free survival rates 无进展生存率

 更多收起网络短语
  • 无疾病进展时间

·2,447,543篇论文数据,部分数据来源于NoteExpress

Progression-free survival

  • abstract: Progression-free survival (PFS) is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.

以上来源于: WordNet

双语例句权威例句

  • Median progression-free survival was 6 months.

    中位无进展生存期6个月

    youdao

  • In both studies, the primary efficacy endpoint was progression-free survival.

    项研究中,主要功效评估指标进展生存期。

    youdao

  • The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.

    药物联用中值无进展存活期为11.8单独紫杉醇获得的5.9个月的倍。

    youdao

更多双语例句
  • The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared to 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant.

    WSJ: Roche Breast-Cancer Treatment Advances

  • In a tougher measure of efficacy that takes into account how long patients lived, called progression-free survival, Thalomid more than doubled the length of time patients lived, to 57 weeks.

    FORBES: Thalomid Fuels Celgene's Rise

  • While the drug combo did meet the first goal of increasing progression-free survival, it failed to prolong overall survival beyond what is normal for patients on chemotherapy without Erbitux.

    FORBES: Market Scan

更多权威例句
$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定